Adrenoceptors in the Eye – Physiological and Pathophysiological Relevance

Ruan, Yue; Buonfiglio, Francesco; Gericke, Adrian

doi:10.1007/164_2023_702

Cited by 2 publications

(1 citation statement)

References 350 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Remarkably, control patients from the GHS group were more frequently taking antihypertensives, especially β-blockers. Intriguingly, βadrenoceptors were shown to be expressed in the cornea, limbus, conjunctiva and lacrimal glands and involved in corneal regeneration, the pathophysiology of allergic conjunctivitis and dry eye disease (Böhm et al, 2023;Diebold et al, 2001;Jun et al, 2022;Ruan et al, 2023;Yuan et al, 2021). Considering the local application of β-blockers to the eye with limited side effects, exploring the potential of β-adrenoceptors as targets for treating PHSCO is warranted.…”

Section: Discussionmentioning

confidence: 99%

Peripheral hypertrophic subepithelial corneal opacification – Role of tear secretion, medication and systemic diseases

Riedl,

Misirkhanova,

Wasielica‐Poslednik

et al. 2024

Acta Ophthalmologica

View full text Add to dashboard Cite

BackgroundPeripheral hypertrophic subepithelial corneal opacification (PHSCO) is a corneal disease that may severely affect vision. The major goal of this study was to test the hypothesis that tear secretion, medication and systemic diseases are associated with PHSCO.MethodsThis is a retrospective, case–control study conducted at the Department of Ophthalmology, University Medical Center of the Johannes Gutenberg University Mainz. We analysed medical records of patients diagnosed with PHSCO. Sex, age, Schirmer's test II, general medication and medical history were assessed and compared to an age‐ and sex‐matched control group from the Gutenberg Health Study (GHS).ResultsOne hundred ninety‐five eyes of 112 patients with PHSCO were included. Eighty‐eight patients were female with a mean age of 55.3 ± 14.7 years (23–89 years) and 24 patients were male with a mean age of 59.3 ± 12.6 years (38–84 years). In 83 patients (74.1%) both eyes were involved. The Schirmer's test II was significantly reduced in patients with PHSCO compared to the GHS control group (p < 0.001). Patients with PHSCO were more frequently administered artificial tears and steroid eye drops (p < 0.001) and were more hyperopic than healthy controls (p = 0.01). Systemic diseases or medication did not differ markedly between PHSCO and healthy controls.ConclusionReduced tear secretion and more frequent use of artificial tears in patients with PHSCO suggest a link between PHSCO and dry eye disease. The results of the study do not support our hypothesis that PHSCO is associated with systemic diseases. Interestingly, patients with PHSCO were less frequently on β‐blockers than control subjects.

show abstract

Section: Discussionmentioning

confidence: 99%